608
Participants
Start Date
December 31, 2021
Primary Completion Date
November 30, 2025
Study Completion Date
September 30, 2026
Salbutamol
Patients assigned to the active group will be treated with 0.15 mg/kg body weight (diluted in 3 mL 0.9% NaCl) nebulized salbutamol (Ventolin®, GlaxoSmithKline, Dublin, Ireland) for 30 min.
0,9% Chloride Sodium
3 mL nebulized 0.9% NaCl administered for 30 min.
RECRUITING
Medical University of Warsaw, Warsaw
University of Ottawa
OTHER
Jagiellonian University
OTHER
Pomeranian Medical University Szczecin
OTHER
Poznan University of Medical Sciences
OTHER
Jan Biziel University Hospital No 2 in Bydgoszcz
OTHER
Neonatology Unit, Specialist Hospital No 2, Bytom
UNKNOWN
University of Rzeszow
OTHER
University in Zielona Góra
OTHER
Medical University of Warsaw
OTHER